Featured Research

from universities, journals, and other organizations

B cells produce antibodies 'when danger calls, but not when it whispers'

Date:
May 15, 2014
Source:
University of California - Los Angeles
Summary:
The immune system's B cells protect us from disease by producing 'smart bullets' that target invaders such as pathogens and viruses. But how do B cells know whether a threat is real and whether to start producing these weapons? An international team of life scientists shows how these cells respond only to true threats.

Mutations in the B cell's key molecular circuit in chickens, shown in green, resulted in ambiguity about whether the threshold, where the 0 line is, had been reached. Without these mutations, there were no such ambiguities, as the blue dots show.
Credit: Japan's RIKEN Center for Integrative Medical Sciences

The immune system's B cells protect us from disease by producing antibodies, or "smart bullets," that specifically target invaders such as pathogens and viruses while leaving harmless molecules alone. But how do B cells determine whether a threat is real and whether to start producing these weapons?

An international team of life scientists shows in the May 16 issue of the journal Science how and why these cells respond only to true threats.

"It is critical for B cells to respond either fully or not at all. Anything in between causes disease," said the study's senior author, Alexander Hoffmann, a professor of microbiology, immunology and molecular genetics in the UCLA College of Letters and Science. "If B cells respond wimpily when there is a real pathogen, you have immune deficiency, and if they respond inappropriately to something that is not a true pathogen, then you have autoimmune disease."

The antibodies produced by B cells attack antigens -- molecules associated with pathogens, microbes and viruses. A sensor on the cell's surface is meant to recognize a specific antigen, and when the sensor encounters that antigen, it sends a signal that enables the body's army of B cells to respond rapidly. However, there may be similar molecules nearby that are harmless. The B cells should ignore their signals -- something they fail to do in autoimmune diseases.

So how do the B cells decide whether to start producing antibodies?

"These immune cells are somewhat hard of hearing, which is appropriate because the powerful and potentially destructive immune responses should jump into action only when danger calls, not when it whispers," said Hoffmann.

The B cells make their response only when a rather high threshold is reached, Hoffmann and his colleagues report. A small or moderate signal -- from a harmless molecule, for instance -- gets no response, which reduces the risk of false alarms.

"It's like your car's airbag, which won't be deployed unless you really need it," Hoffmann said. "You can imagine that if the airbag were poorly designed and if you brake very hard or have a slight accident, it could deploy slowly and be useless. You want it to deploy fully or not at all. That is what the B cell does when deciding whether it confronts something that is truly pathogenic or harmless. No B cell responds partially."

We have billions of B cells, and each one creates this threshold through a molecular circuit involving two molecules. One of these molecules, known as CARMA1, activates the other, IKKb, which further activates the first one.

"Positive feedback between the two causes infinite growth, and once you trigger it, there is no way to turn it off until the smart bullets are shot," said Hoffmann, whose research aims to understand and decode the language of cells. "But a second feature of positive feedback is that it can create a threshold only above which this runaway activation occurs."

He and his colleagues developed mathematical equations based on the molecular circuit and were then able to simulate, virtually, B cell responses. The team's resulting predictions were tested experimentally by their collaborators at the Laboratory for Integrated Cellular Systems at Japan's RIKEN Center for Integrative Medical Sciences. In one part of the study, the researchers made specific mutations in IKKb so that it could not signal back to CARMA1. They also made mutations in CARMA1 to prevent it from receiving the signal from IKKb. In both cases, the B cells responded partially, some of the time, like a weakly inflating airbag.

"It became a gray-zone response rather than a black-and-white response," said Hoffmann, who constructs mathematical models of biology.

The research could lead to better diagnosis of disease if patients with an autoimmune disorder, such as lupus, have a defect in this molecular circuit.


Story Source:

The above story is based on materials provided by University of California - Los Angeles. The original article was written by Stuart Wolpert. Note: Materials may be edited for content and length.


Journal Reference:

  1. H. Shinohara, M. Behar, K. Inoue, M. Hiroshima, T. Yasuda, T. Nagashima, S. Kimura, H. Sanjo, S. Maeda, N. Yumoto, S. Ki, S. Akira, Y. Sako, A. Hoffmann, T. Kurosaki, M. Okada-Hatakeyama. Positive Feedback Within a Kinase Signaling Complex Functions as a Switch Mechanism for NF-B Activation. Science, 2014; 344 (6185): 760 DOI: 10.1126/science.1250020

Cite This Page:

University of California - Los Angeles. "B cells produce antibodies 'when danger calls, but not when it whispers'." ScienceDaily. ScienceDaily, 15 May 2014. <www.sciencedaily.com/releases/2014/05/140515154134.htm>.
University of California - Los Angeles. (2014, May 15). B cells produce antibodies 'when danger calls, but not when it whispers'. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/05/140515154134.htm
University of California - Los Angeles. "B cells produce antibodies 'when danger calls, but not when it whispers'." ScienceDaily. www.sciencedaily.com/releases/2014/05/140515154134.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins